Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013-07-01
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
ABSTRACT
PURPOSE
To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer.
PATIENTS AND METHODS
Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women). Primary end points were time to local or regional recurrence, frequency of mastectomy, breast cancer-specific survival, time to distant metastasis, and overall survival (OS).
RESULTS
Median follow-up for treated patients is now 12.6 years. At 10 years, 98% of patients receiving TamRT (95% CI, 96% to 99%) compared with 90% of those receiving Tam (95% CI, 85% to 93%) were free from local and regional recurrences. There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or OS between the two groups. Ten-year OS was 67% (95% CI, 62% to 72%) and 66% (95% CI, 61% to 71%) in the TamRT and Tam groups, respectively.
CONCLUSION
With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains. However, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tam remains a reasonable option for women age ≥ 70 years with ER-positive early-stage breast cancer.
Related Questions
My institution is considering a major investment/purchase of this technology to complement our existing array of breast radiotherapy options.
New answer by Radiation Oncologist at Memorial University Medical Center (September 22, 2013)
I use the intrabeam IORT system and have treated about 90 patients. 22% have been given adjuvant whole breast or breast/axilla/scf xrt. The toxicity of IORT is significantly l...
The Hughes study looked at women > 70 years of age. In light of the PRIME II results, can women aged 65 - 70 avoid RT or is longer follow up needed...
New answer by Radiation Oncologist at Northwestern University (March 18, 2016)
I agree with the above answers and would like to expand a bit. What is so special about being over 70 (or over 65 for that matter) when your breast cancer is diagnosed? Not mu...
Would your management change if the patient had extensive DCIS?
New comment by Radiation Oncologist at AdventHealth Orlando (previously Florida Hospital) ( December 15, 2016)
Yikes! That's absolutely not how I intended my response to be interpreted. I certainly agree with you, @Leonard Prosnitz, that using radiation in any disease for the sole bene...
What is the maximal amount of time you would allow between the surgery the start of adjuvant RT? What other factors would you consider when deciding w...
New answer by Radiation Oncologist at Memorial Sloan Kettering Cancer Center (November 24, 2017)
Given the low-risk nature of T1N0 luminal lesions among older patients (per the CALGB 9343 and Prime II trials), the conundrum of whether to pursue adjuvant endocrine therapy,...
CALGB 9343 included ER positive patients but did not separate them out based on herceptin status. Does the study help inform their risk?
New answer by Radiation Oncologist at New York University School of Medicine (January 16, 2018)
As your question states, neither CALGB 9343 nor the PRIME II study assessed HER2 status of its patients as both of these trials commenced prior to the routine testing of HER2 ...
We often treat elderly women with lumpectomy and adjuvant hormonal therapy without radiation. I am concerned about how to proceed after the 5 year poi...
New answer by Medical Oncologist at Yale School of Medicine (November 15, 2017)
It is always difficult to make a recommendation for endocrine therapy duration when optimal duration is unknown. Looking at CALGB 9343 (Hughes et al, JCO 2013), in which women...
There has been shifting concerns with medication side effects (such as osteoporosis, blood clots), duration, and potential non-compliance.
New answer by Radiation Oncologist at Cleveland Clinic (August 15, 2018)
I think it is time to re-evaluate the concept of treatment de-intensification with endocrine therapy alone due to the toxicities, and compliance associated with endocrine ther...
Would multifocality, multicentricity, LVSI, N1mi, etc affect your decision making?
New answer by Radiation Oncologist at Washington University School of Medicine (October 29, 2018)
I wholeheartedly agree with @David E. Wazer and @Leonard Prosnitz. Their answers do take us a few steps away from the original question to the larger issue of what if any...
Is this new SSO choosing widely guideline being widely adopted and are there any concerns regarding this for clinical practice?
New comment by Radiation Oncologist at Mountain Radiation Oncology ( October 3, 2019)
I believe the average life expectancy of a 70 year old woman is about 17 years. Of course, longer for those without comorbidities.
New answer by Medical Oncologist at Siri Onclogy and hematology Infusion Service (August 11, 2019)
I assume you mean lymph node irradiation. This is very clearly dependent on age. Based on retrospective studies which included virtually no patients over 70, I probably would ...